| Modulating NRF2 in Disease: Timing Is Everything |
39 |
| Environmental Obesogens: Mechanisms and Controversies |
36 |
| The Opioid Epidemic: Crisis and Solutions |
35 |
| TRP Channels as Potential Drug Targets |
35 |
| Therapeutic Oligonucleotides: State of the Art |
34 |
| Targeting Epigenetics in Cancer |
30 |
| Organoids for Drug Discovery and Personalized Medicine |
28 |
| The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease |
27 |
| Mechanism of Neonicotinoid Toxicity: Impact on Oxidative Stress and Metabolism |
25 |
| The Exposome: Molecules to Populations |
25 |
| Repairing Mitochondrial Dysfunction in Disease |
24 |
| Development and Therapeutic Potential of Small-Molecule Modulators of Circadian Systems |
23 |
| KCNQ-Encoded Potassium Channels as Therapeutic Targets |
23 |
| Pharmacologic Targeting of Hypoxia-Inducible Factors |
23 |
| Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems |
22 |
| Physiologically Based Pharmacokinetic and Pharmacodynamic Analysis Enabled by Microfluidically Linked Organs-on-Chips |
20 |
| Adverse Effects of Nutraceuticals and Dietary Supplements |
19 |
| Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants |
19 |
| Metals and Mechanisms of Carcinogenesis |
19 |
| Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery |
18 |
| Adhesion G Protein-Coupled Receptors as Drug Targets |
18 |
| Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders |
16 |
| Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient |
15 |
| The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease |
15 |
| Novel Clinical Toxicology and Pharmacology of Organophosphorus Insecticide Self-Poisoning |
14 |
| Toward Therapy of Human Prion Diseases |
14 |
| Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities |
13 |
| The Placebo Effect in Pain Therapies |
12 |
| Impacts of the Human Gut Microbiome on Therapeutics |
12 |
| Harnessing the Properties of Natural Products |
11 |
| Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies |
11 |
| Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes |
11 |
| Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited |
10 |
| Muscle Wasting Diseases: Novel Targets and Treatments |
10 |
| The Conducted Vasomotor Response: Function, Biophysical Basis, and Pharmacological Control |
10 |
| Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities |
9 |
| The Ethnopharmacologic Contribution to Bioprospecting Natural Products |
9 |
| The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder |
8 |
| Surviving in the Valley of Death: Opportunities and Challenges in Translating Academic Drug Discoveries |
8 |
| Lung Cancer Heterogeneity and New Strategies for Drug Therapy |
7 |
| The Genetics of Pain: Implications for Therapeutics |
7 |
| Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions |
6 |
| Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy |
6 |
| New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy |
6 |
| Convergent Neuronal Plasticity and Metaplasticity Mechanisms of Stress, Nicotine, and Alcohol |
5 |
| Therapeutic Approaches to the Treatment of Tinnitus |
5 |
| Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials |
4 |
| Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation |
4 |
| Moving from the Trial to the Real World: Improving Medication Adherence Using Insights of Implementation Science |
4 |
| Recent Developments in Understanding Barrier Mechanisms in the Developing Brain: Drugs and Drug Transporters in Pregnancy, Susceptibility or Protection in the Fetal Brain? |
4 |
